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Abstract: Primary hypertension in children is increasing in prevalence with many cases likely going undiagnosed. The prevalence is 
currently estimated at between 3%–5% in the United States and may be higher in certain ethnic groups. Primary hypertension, once 
felt to be rare in children, is now considered to be about five times more common than secondary hypertension. This review provides 
information to guide physicians through an organized approach to: 1) screening children and adolescents for hypertension during routine 
visits; 2) using normative percentile data for diagnosis and classification; 3) performing a clinical evaluation to identify the presence of 
co-morbidities; 4) initiating a plan of care including subsequent follow-up blood pressure measurements, therapeutic lifestyle changes 
and pharmacologic therapies.
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Introduction
The  prevalence  of  hypertension  in  children  and 
  adolescents has increased in the past several years, 
likely as a result of the rise in childhood overweight 
and  obesity. The  prevalence  is  currently  estimated 
at between 3%–5% in the United States and may be 
higher in certain ethnic groups, such as non-Hispanic 
blacks and Mexican Americans.1–3 This may   actually 
be an underestimate as some experts believe that clini-
cians fail to recognize high blood pressure in   children 
and  adolescents.3  Unlike  in  the  adult  population 
where absolute cutoffs exist based on   observational 
studies, classification of blood pressure in children 
and adolescents is based on normative data derived 
from a national database of 70,000 healthy children 
in the US.4
Blood  pressure  in  children  is  classified  as: 
(1)  normal  (systolic  and  diastolic  blood  pressure 
[SBP  and  DBP  respectively]  ,90th  percentile); 
(2)   pre-hypertension (SBP and DBP 90th to ,95th 
percentile or exceeding 120/80); (3) Stage 1 hyper-
tension (95th percentile to 99th plus 5 mmHg); and 
(4)  Stage  2  hypertension  (.99th  percentile  plus 
5 mmHg) based on sex, age and height on at least 
three  separate  measurements.4  Patients  are  felt  to 
have “white-coat hypertension” when BP is normal 
outside a medical provider’s office but 95th percen-
tile or greater in the office. Children have hyperten-
sion when blood pressures are persistently elevated 
greater than 140/90 or greater than the 95th percen-
tile based on these classifications.
The Fourth Report on the Diagnosis, Evaluation, 
and Treatment of High Blood Pressure in Children 
and Adolescents is still the major reference point for 
recommendations regarding the diagnosis and treat-
ment of hypertension in children and   adolescents.4 
In  2009,  the  European  Society  of  Hypertension 
released  updated  guidelines  on  management  of 
high blood pressure in children and adolescents and 
used the same criteria to define hypertension as the 
Fourth Report.5 The guidelines suggest an emerg-
ing role for the use of ambulatory and home blood 
pressure monitoring in children and adolescents for 
the diagnosis of hypertension especially in children 
with isolated clinic hypertension and assessment of 
response to treatment.5 Isolated clinic hypertension 
is defined as blood pressure measurements .95th 
percentile in the office and ,90th percentile in the 
outpatient setting.4
Special considerations exist for measuring blood 
pressure  in  children  and  adolescents.  In  general, 
children greater than 3 years old should have their 
blood  pressure  routinely  measured  during  each 
health  care  encounter.  Blood  pressure  should  be 
measured by auscultation as BP normative data was 
obtained using auscultation and there are many limi-
tations to the use of automated oscillometric devices 
in children.4,5 A study done after the release of the 
Fourth Report recommendations involving 390 chil-
dren  at  a  pediatric  hypertension  clinic  found  that 
74% of initial readings done at a standard vital sign 
station were higher (13.2 ± 8.9 mmHg for SBP and 
9.6 ± 7.6 mm Hg for DBP) than those obtained in 
the examination room using protocols established 
by the Fourth Report.1 As a result, the authors of this 
study suggest repeating blood pressures that are ini-
tially elevated.
Once  the  blood  pressure  is  obtained,  it  should 
be  classified  by  percentile  based  on  age,  sex  and 
height percentile, as determined by the revised CDC 
growth charts.4 Because these charts may be cum-
bersome  to  use  in  practice,  a  simplified table  was 
created to identify cutoffs for children and adoles-
cents  needing  further  evaluation.6  A  more  simpli-
fied blood pressure table was developed for children 
ages 3–18 for providers in the outpatient setting by 
  Mitchell  et  al  to  improve  recognition  of  pediatric 
hypertension in the outpatient setting. Blood pressure 
elevations  that  exceed  these  levels  should  prompt 
referral to   standardized tables to confirm a diagno-
sis of   hypertension.7   On-line, web-based calculators 
also exist that can classify blood pressure by percen-
tile  to  quickly  and  appropriately  classify  children 
and   adolescents. An example of one online calcula-
tor can be found at Baylor   College of Medicine Body 
  Composition Lab in Houston, Texas.8
Although less is known about the long-term conse-
quences of hypertension in children and adolescents, 
elevated blood pressure in childhood and adolescence 
is a risk factor for hypertension and cardiovascular 
disease in adults and may be associated with left ven-
tricular hypertrophy (LVH) at the time of   diagnosis.4 
Primary hypertension, once felt to be rare in children, 
is now considered to be about five times more common  Hypertension in children and adolescents
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than secondary hypertension. Primary   hypertension is 
more common in older children and adolescents and 
is usually characterized by Stage 1 hypertension.4 It is 
commonly associated with a   family history of hyper-
tension or cardiovascular disease.9 Secondary causes 
of hypertension are more common in children less 
than 6 years of age and are usually renal or renovas-
cular in origin.10
The  Fourth  Report  outlines  the  recommended 
clinical evaluation for children and adolescents with 
confirmed hypertension. (See Table 1) One of the key 
aspects of this evaluation is to identify the presence of 
co-morbidities that may alter treatment goals for indi-
vidual patients. Attention should be paid to the recog-
nition of sleep apnea since it may be associated with 
higher blood pressure in children and adolescents and 
it is more common in the overweight. In addition, 
echocardiography is recommended at time of diag-
nosis to determine if LVH is present. The presence of 
LVH is a marker for target-organ damage and an indi-
cation for more aggressive therapy. Table 2 outlines 
frequency  of  BP  measurement  and  indications  for 
therapeutic lifestyle changes and/or pharmacotherapy 
based on stage of hypertension.
In general, the goal of therapy is to reduce the 
blood  pressure  to  less  than  the  95th  percentile  in 
children  and  adolescents  with  no  co-morbidities.4 
Some experts recommend a goal of less than the 90th 
  percentile for this group.5 In the setting of chronic 
  kidney disease, diabetes or target-organ damage such 
as LVH, the goal BP is less than the 90th percentile 
for sex, age, and height.4 There may be a role for 
lowering blood pressure below the 75th percentile in 
patients with proteinuria.5
Nonpharmacologic management of hypertension 
includes  weight  loss,  aerobic  exercise,  restriction 
of salt intake, and stress reduction.11,12 Overweight 
increases the risk for the development of hypertension 
significantly.2,5 Although there is limited evidence, 
types of aerobic exercise thought to be most bene-
ficial are walking, running, cycling, or   swimming. 
The  high  degree  of  patient  and  family  commit-
ment required may limit their   effectiveness.13 Dur-
ing aerobic exercise, peripheral vascular resistance 
decreases, causing an increase in systolic blood pres-
sure (SBP) and mean arterial pressure (MAP) and 
a reduction in the   diastolic blood pressure (DBP); 
however, in static exercise such as weight lifting, 
the SBP, DBP, and MAP increase significantly and 
can exceed the values for aerobic   exercise. There are 
usually both components in   exercise so   participation 
should  only  be  granted  when  the  demands  for 
  training and   participating in the activity have been 
examined and determined that the child is not at risk 
for a catastrophic event from an abrupt increase in 
BP.11 The preparticipation physical evaluation work-
ing  group  recommends  those  with  Stage  2  hyper-
tension  avoid  heavy  weight  and  power  lifting, 
bodybuilding, strength training and other high-static 
component  sports.  Those  with  sustained  Stage  1 
hypertension need individualized evaluation prior to 
participation.14
The Dietary  Approaches to Stopping   Hypertension, 
or DASH diet, is recommended although its effec-
tiveness in children and adolescents with essential 
hypertension  has  not  been  extensively  studied.15 
The diet emphasizes the intake of fruits, vegetables, 
low-fat dairy and whole grains and limits intake of 
high fat foods and refined sugar. It has been shown 
to  be  effective  in  adults  to  reduce  blood  pres-
sure and has no real side effects.12 One study did 
review incorporation of the DASH diet in children 
with diabetes and hypertension and demonstrated 
a substantial reduction in the propensity of Type 1 
  diabetic children to have hypertension but this was 
not observed in those with Type 2 diabetes.16 Most 
of the   children with Type 2 diabetes were obese in 
the study which may explain the lack of improve-
ment in this population.
While these therapies may be effective in reduc-
ing the blood pressure to the targeted levels, phar-
macologic therapy will need to be considered if they 
do not. The etiology of the hypertension, the antici-
pated benefits for the child, and the potential adverse 
effects  should  guide  the  choice  of  medication.4,17 
Given the lack of long-term pediatric data on benefits 
of   therapy and adverse effects on growth and devel-
opment, medications should be started cautiously.18 
First line antihypertensive medications for children 
include  angiotensin-converting  enzyme  inhibitors 
(ACEIs), angiotensin receptor blockers (ARBs), cal-
cium channel blockers (CCBs), beta-blockers (BBs) 
and    diuretics.  Treatments  specific  for    secondary 
causes of hypertension and severe hypertension are Stephens et al
16  Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 2012:6
Table 1. Clinical evaluation of confirmed hypertension.
study or procedure purpose Target population
Evaluation for identifiable causes
History, including sleep history, 
family history, risk factors, diet, and 
habits such as smoking and drinking 
alchohol; physical examination
History and physical examination 
help focus subsequent evaluation
All children with persistent BP $ 95th 
percentile
BUN, creatinine, electrolytes, 
urinalysis, and urine culture
R/O renal disease and chronic 
pyelonephritis
All children with persistent BP $ 95th 
percentile
CBC R/O anemia, consistent with chronic 
renal disease
All children with persistent BP $ 95th 
percentile
Renal U/S R/O renal scar, congenital anomaly, 
or disparate renal size
All children with persistent BP $ 95th 
percentile
evaluation for comorbidity
Fasting lipid panel, fasting glucose Identify hyperlipidemia, identify 
metabolic abnormalities
Overweight patients with BP at 
90th–94th percentile; all patients with 
BP $ 95th percentile. Family history 
of hypertension or cardiovascular 
disease. Child with chronic renal 
disease
Drug screen Identify substances that might cause 
hypertension
History suggestive of possible 
contribution by substances or drugs
Polysomnography Identify sleep disorder in association 
with hypertension
History of loud, frequent snoring
evaluation for target-organ damage
echocardiogram Identify LvH and other indications of 
cardiac involvement
Patients with comorbid risk factors* 
and BP 90th–94th percentile; all 
patients with BP $ 95th percentile
Retinal exam Identify retinal vascular changes Patients with comorbid risk factors* 
and BP 90th–94th percentile; all 
patients with BP $ 95th percentile
Further evaluation as indicated
Ambulatory BP monitoring Identify white-coat hypertension, 
abnormal diurnal BP pattern, BP 
load
Patients in whom white-coat 
hypertension is suspected, and when 
other information on BP pattern is 
needed
Plasma renin determination Identify low renin, suggesting 
mineralocorticoid-related disease
Young children with Stage 1 
hypertension and any child or 
adolescent with Stage 2 hypertension
Positive family history of severe 
hypertension
Renovascular imaging 
•  Isotopic scintigraphy (renal scan) 
•  Magnetic resonance angiography 
•  Duplex Doppler flow studies 
•  3-Dimensional CT 
• Arteriography: DSA or classic
Identify renovascular disease Young children with Stage 1 
hypertension and any child or 
adolescent with Stage 2 hypertension
Plasma and urine steroid levels Identify steroid-mediated 
hypertension
Young children with Stage 1 
hypertension and any child or 
adolescent with Stage 2 hypertension
Plasma and urine catecholamines Identify catecholamine-mediated 
hypertension
Young children with Stage 1 
hypertension and any child or 
adolescent with Stage 2 hypertension
notes: *Comorbid risk factors also include diabetes mellitus and kidney disease. Reproduced with permission from Pediatrics, vol. 114, Page 562, 
copyright 2004 by the AAP.
Abbreviations: BP, blood pressure; BUN, blood urea nitrogen; CBC, complete blood count; CT, computerized tomography; DSA, digital subtraction 
angiography; LvH, left ventricular hypertrophy; R/O, rule out; U/S, ultrasound. Hypertension in children and adolescents
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beyond the scope of this article. Hypertension will 
refer  to    essential  or  primary  hypertension  for  the 
remainder of the article unless specified otherwise.
Mechanism of Action, Metabolism, 
and Pharmacokinetic Profile
Most pharmacokinetic data for children has come from 
adult trials. With the passage of the Food and Drug 
Administration Modernization Act in 1997, there has 
been an increase in pharmaceutical-sponsored trials 
evaluating antihypertensive medications in children. 
This was reinforced with The Best Pharmaceutical 
for Children Act passed in 2002 and expanded by the 
Pediatric Research Equity Act passed in 2003 requir-
ing all applications for new drugs to include pediatric 
assessment data unless the pharmaceutical company 
obtained a waiver or deferral.12
Angiotensin-Converting enzyme 
inhibitors and angiotensin receptor 
blockers
ACEIs are one of the most commonly used antihy-
pertensive medications in the pediatric population. In 
general, they have few adverse effects in standard doses 
and  have  convenient  dosing  schedules  to  improve 
adherence. This  makes  them  attractive  choices  for 
pediatric  hypertension  especially  in  adolescents.19 
Angiotensin-converting  enzyme  (ACE)  facilitates 
the conversion of angiotensin I to angiotensin II and 
the degradation of bradykinin.   Angiotensin   receptor 
blockers  (ARBs)  selectively  inhibit  the 
binding of angiotensin II to the angiotensin II type 1 
receptors.19
Angiotensin II produces arterial vasoconstriction 
and activation of the renin-angiotensin system pro-
moting salt and water reabsorption in the distal tubules 
mediated by aldosterone. Angiotensin II also stimu-
lates the sympathetic nervous system and has a direct 
inotropic  effect  on  the  heart.  Bradykinin  produces 
vasodilatation via prostaglandin-mediated effects on 
endothelial cells. ACEIs prevent the conversion of 
angiotensin I to angiotensin II which reduces arte-
rial vasoconstriction and the salt and water retention 
facilitated by stimulation of aldosterone release by 
angiotensin II and with reduced degradation of bra-
dykinin,  arterial  vasodilation.  Blood  pressure  falls 
gradually until ACE is inhibited by 90% rather than 
in a dose response effect.20–23 Angiotensin II produces 
vasoconstriction  at  both  the  afferent  and  efferent 
arterioles with preferential increases at the efferent 
arteriole; therefore ACEIs increase blood flow to the 
kidney despite lowering blood pressure. Additionally, 
the sulfhydryl group present on captopril is thought to 
have an anti-inflammatory effect.24 ACEIs are sepa-
rated by their route of elimination, presence of a sulf-
hydryl group, and requirement for activation.20
Calcium channel blockers
Calcium channel blocking antihypertensives inhibit 
the influx of extracellular calcium into the cellular 
membrane of the smooth muscle and other contrac-
tile cells by blocking the transmembrane transport of 
  calcium. This results in reduced contractility and arte-
riolar smooth muscle tone in a dose-dependent   fashion. 
Dihydropyridines are the major class of CCBs used 
to treat essential hypertension in children because of 
their relative selectivity for arteriolar smooth   muscle. 
These include amlodipine, isradipine, and nifedipine. 
The  non-dihydropyridines,  another  class  of  CCBs 
that includes verapamil and diltiazem, have greater 
affinity for cardiac cells thus reducing contractility 
and altering conduction at the sinus node pacemaker 
and atrioventricular node respectively. Additionally, 
increases in glomerular filtration rate (GFR) and renal 
blood  flow  occur  with  therapy  presumably  related 
to the reduction in renal vascular resistance.11,19–21,23 
Non-dihydropyridines are rarely used for the treatment 
of essential hypertension in children and adolescents 
because of their effects on cardiac functioning.22
Beta-Blockers
Beta-adrenergic  antagonists  reduce  the  effect  of 
endogenous  catecholamines  on  beta-adrenergic 
receptors. There are three identified types of   receptors 
designated β1, β2, and β3. β1-adrenergic receptors are 
found primarily in the heart and   kidney; β2-adrenergic 
receptors  are  located  in  multiple  areas  particu-
larly  the  lung,  vascular  smooth  muscle,  and  skel-
etal   muscle; and β3-adrenergic receptors are located 
in  adipose  tissue.21  In  general,  BBs  competitively 
block  β1-adrenergic  receptors  and  β2-adrenergic 
receptors dependent upon the selectivity of the indi-
vidual  drug.19  These  medications  are  separated  by 
several  characteristics,  including  cardioselectivity, 
alpha adrenergic activity, hydrophilic and lipophilic 
properties  and  intrinsic  sympathomimetic    activity.    Hypertension in children and adolescents
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  Assessment  of  these    properties  can  be  useful  in 
selecting the   appropriate BB for use in a particular 
patient.11
Included in this category are BBs that also have 
α-adrenoreceptor  blocking  properties.  They  exert 
their  effect  primarily  by  competitive  blockade  of 
peripheral  post-synaptic  alpha1-receptors  produc-
ing  vasodilation.19–21  Nonselective  beta-blocker  use 
has been associated with development of diabetes in 
contrast to the cardioselective β-antagonists.25
Diuretics
Diuretics are used primarily as a second medication 
when adequate blood pressure has not been attained 
with monotherapy especially in adolescents and in 
children with renal disease with high volume states. 
The two types primarily used are thiazide and loop 
diuretics. Thiazide diuretics exert their effect on the 
distal tubule in the kidney to decrease sodium and 
water  reabsorption  and  increase  potassium  secre-
tion in an ion exchange mechanism by inhibiting the 
  sodium-chloride membrane transporter.  With long term 
use, the thiazides produce   vasodilatation. Although 
the mechanism of action is not   thoroughly under-
stood, it is postulated it may be due to a decrease in 
interstitial volume, a decrease in intracellular sodium 
that alters intracellular calcium, or a change in cel-
lular receptors to vasoconstrictor substances. There-
fore, initial blood pressure reduction appears to occur 
due to a decrease in plasma volume and cardiac out-
put and then occurs due to a reduction in peripheral 
resistance. Their efficacy is dependent on the glom-
erular filtration rate (GFR). They are most efficacious 
when  the  GFR  is  .50  ml/minute  and  ineffec-
tive when the GFR is ,30 ml/minute.19–21 Thiazide 
diuretics  produce  elevations  in  blood  glucose  and 
insulin levels.26
Loop diuretics exert their effect at the ascending 
limb of the loop of Henle by decreasing the reabsorp-
tion of sodium and water by inhibiting the sodium-
potassium-chloride  membrane  transporter.  They 
also increase renal blood flow by reducing renovas-
cular resistance. They are more potent than thiazide 
diuretics but their efficacy also decreases as GFR is 
reduced.19,20
Please see Table 3 for information related to peak 
level, half life, and excretion. Clinicians should be 
aware that not all of these medications have specific 
pediatric FDA approval or labeling. Dosage informa-
tion should be confirmed prior to use.
Clinical Studies, Safety and Efficacy
Angiotensin converting enzyme  
inhibitors
Safety and efficacy data are available for most of the 
ACEI. Enalapril and lisinopril both produce a dose-
  dependent  reduction  in  blood  pressure.    Minimum 
effective  dosages  range  from  0.08  mg/kg/day  to 
0.6 mg/kg/day and were well tolerated.12,27,28   However, 
fosinopril did not produce the same dose response 
reduction in blood pressure as that seen in the enal-
april  and  lisinopril  studies,  but  did  demonstrate  a 
significant reduction in SBP and DBP. The study par-
ticipants were ages 6–16 years of age. Fosinopril is 
only recommended for children weighing $50 kg.12,29 
Ramipril studied in children with chronic renal dis-
ease reduced the BP at 24 hours at a daily dose of 
6 mg/m2 and at a dose of 2.5 mg/m2 reduced BP and 
proteinuria  in  children  with  essential  hypertension 
and in those with chronic kidney disease.5
Common side effects associated with ACEI medi-
cations  include  hypotension,  cough,  hyperkalemia 
and elevated creatinine. Monitoring of serum electro-
lytes and creatinine are recommended with initiation 
of therapy and periodically to monitor the potassium 
and creatinine.
Other  adverse  reactions  include    angioedema, 
headache,  anemia,  tachycardia,  vertigo,  dyspnea, 
rash, and leucopenia.27,28 One study found that chil-
dren between 2–16 years of age receiving enalapril 
or  captopril  developed  neutrophilic  hypersegmen-
tation.30 One retrospective study of   lisinopril found 
no  effect  on  age-specific  growth  patterns  despite 
the varying medical conditions of the   participants.28 
A  meta-analysis  of  studies  evaluating  ethnic  dif-
ferences in children treated with ACEI suggested a 
difference between black and white children to the 
antihypertensive  effects  of  ACEI.  Black  children 
demonstrated  a  lesser  antihypertensive  response 
than  white  children.31 ACEI  are  contraindicated  in 
patients with bilateral renal artery stenosis.
Infants have an exaggerated response to ACEIs and 
should receive smaller weight-adjusted dosages than 
older children. This may be related to their dependence 
on the renin-angiotensin-aldosterone system for main-
tenance of renal blood flow. They can have severe, Stephens et al
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Table 3. Pharmacologic therapy.
Drug peak level Half Life excretion Dosing 
schedule
Ace Inhibitors
  Benazepril (prodrug) 2–4 h  
1–2 fasting
5 h Renal  
(11%–12% biliary)
QD
  Captopril 3 h Urine TID
  Fosinopril (prodrug) 3 h 11–13 h Urine = Bile/Feces QD
  Lisinopril 5–6 h 12 h Urine QD
  Quanapril (prodrug) 1–2 h 2 h (elimination)  
25 (terminal)
Bile/Feces 37%  
Urine 61%
QD
  enalapril (prodrug) 3–4 h 14h ages 12–16  
. 16 h ages 6– , 12
Bile/Feces 33%  
Urine 60%
QD-BID
ARBs
  Candesarten (prodrug) 4 h 6 h ages 1–17 Bile/Feces 67%  
Urine 33%
QD
  Irbesartan 1–2 h 11–15 h Bile/Feces 80%  
Urine 20%
QD
  Olmesartan (prodrug) 1.4–2.6 h 12–18 h Bile/Feces 60%  
Urine 3%–15%
QD
  Telmisartan 1–1.5 h 27–28 h Bile/Feces QD
  Losartan 1–2 h 4–5 h Bile/Feces 60%  
Urine 35%
QD
  valsartan 2–3 h 6 h Bile/Feces 83%  
Urine 13%
QD
calcium channel blockers
 Amlodipine 6–12 h 36–45 h Urine QD
  Nifedipine 25–30 min 2 h Urine QD-BID
  Isradipine 1.5 h 9 h Bile/Feces 25%–30%  
Urine 60–65%
QD
Beta blockers
  Propranolol (non-selective) 1–3 h 4–6 h Urine BID-TID
 Atenolol (selective) 2–4 h 6–7 h Urine QD-BID
  Metropolol (selective) 3–7 h Bile/Feces BID
    Labetalol (selective alpha; non-
selective beta)
6–8 h Bile/Feces 50%  
Urine 50%
BID
  Bisoprolol (selective) 3 h 7–15 h Urine QD
Diuretics
  Hydrochlorothiazide 2–4 h 5–15 h Urine QD
  Furosemide 1–2 h 24 h Bile/Fsssseces 12%  
Urine 88%
QD
4,12,19, 20, 24, 29, 32, 33, 35, 36, 38, 41, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61.
prolonged hypotension with oliguric renal   failure.27 In 
a study with children at least 6 months of age, capto-
pril was given in dosages of 0.5, 1.0, and 2.0 mg/kg. 
Reductions in SBP and DBP were similar and indepen-
dent of dosage; therefore, a dosage of 0.5 mg/kg is rec-
ommended as the starting dose in   children $6 months 
of age.21 ACEI should be avoided in pregnancy and 
used cautiously in those of child-bearing age. ACEI 
exposure during the first trimester can result in major 
congenital  malformations.    Exposure  during  the 
second and third trimesters is associated with fetal 
hypotension, growth restriction, pulmonary and renal 
hypoplasia, anuria, and death.11,27
Angiotensin receptor blockers
Several  studies  have  demonstrated  the  efficacy  of 
ARBs in the treatment of hypertension in children. 
In a systematic review, the ARBs irbesartan, cande-
sartan, and losartan lower SBP and DBP, 10.5 mmHg 
and 6.9 mmHg respectively. They decrease proteinu-
ria by over 50% as well. Losartan reduced DBP in a 
dose dependent fashion at doses from 0.75 mg/kg/day  Hypertension in children and adolescents
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to 1.44 mg/kg/day and was well   tolerated. A small 
  irbesartan study indicated that doses of 75–150 mg/day 
were efficacious in the treatment of hypertension but 
a later study in children ages 6–16 years failed to 
show a significant antihypertensive effect.5,12,32 In the 
Assessment of Efficacy and Safety of Olmesartan in 
Pediatric Hypertension (AESOP) study, two groups 
of  children  ages  6–16  years  of  age  were  enrolled 
and given either low-dose (2.5–5 mg) or high dose 
(20–40 mg) Olmesartan daily for three weeks. Both 
groups  demonstrated  statistically  significant  reduc-
tions in SBP and DBP but much greater in the high-
dose  group.33  Valsartan  demonstrated  efficacy  in 
reducing blood pressure in children aged 1–5 years. 
During this study conducted in four phases, the chil-
dren were randomized to receive low-dose, medium-
dose, or high-dose valsartan. The fourth phase was a 
52 week open label treatment period. Valsartan sig-
nificantly lowered SBP and DBP in all of the dos-
age groups regardless of race or weight. During the 
open-label  phase,  participants  received  either  val-
sartan alone or combined with hydrochlorothiazide. 
By the end of the period, .75% achieved a SBP less 
than the 95th percentile.34,35 Telmisartan at dosages of 
1–2 mg/kg produced significant reductions in SBP in 
children ages 6 to ,18 years of age.36
Generally, ARBs are well tolerated. Side effects 
reported included cough, rhinitis, urinary and gas-
trointestinal infections, headache, dizziness, blurred 
vision,  fatigue,  anemia,  and  hyperkalemia.32  Other 
adverse  reactions  reported  include  rash  and  pruri-
tus,  hypertriglyceridemia,  edema,  leucopenia,  and 
thrombocytopenia.34
The same precautions should be taken in pregnancy 
and in women of child-bearing age as with ACEI. 
Similar  congenital  malformations  seen  with ACEI 
exposure  during  pregnancy  have  been    reported.32 
Studies involving candesartan, losartan, and valsartan 
showed no effect on growth during study periods of 
52 weeks for each.32,34
Calcium channel blockers
The  major  class  of  CCBs  used  in  the  treatment 
of  pediatric  hypertension  is  the  dihydropyridines 
because of their rather selective action on arteriolar 
smooth   muscle.11 Amlodipine, nifedipine, felodipine, 
nicardipine, and isradipine have shown efficacy in 
treating  hypertension  in  children.20  Several  trials 
have  studied  the  efficacy  of  amlodipine  in  the 
treatment of pediatric hypertension. In one study, dos-
ages of 0.06–0.34 mg/kg/day effectively reduced SBP 
in children ages 6 to 16.5 In a prospective study eval-
uating amlodipine, 21 children were given dosages 
based on weight: 5 mg/kg/day for children .70 kg; 
2.5 mg/kg for those 50–70 kg; and 0.05 mg/kg for 
those ,50 kg. Dosing was once daily. The 16 chil-
dren with primary hypertension reached their target 
BP of ,95th percentile for age, weight, and gender.21 
Long-acting nifedipine might be an option in older 
children  that  can  swallow  tablets  but  it  cannot  be 
crushed; therefore, its use is limited in young chil-
dren.21 Nicardipine is similar to nifedipine except it 
does not affect cardiac function. Typically nicardipine 
and isradipine are delivered by continuous intrave-
nous infusion because of their short half-lives. They 
can be rapidly titrated to a desired BP.27 A mean effec-
tive nicardipine dose of 1.8 ± 1.0 µ/kg/min achieved 
a 16% drop in SBP, 23% in DBP, and a 7% increase 
in heart rate within 2.7 ± 2.1 hours after initiation.37 
However, the oral preparation of isradipine was given 
to 12 children over a three year period. There were 
6 boys and 6 girls, ranging in age of 10 months to 
11 years. Initial doses were given at 0.1 mg/kg for all 
children and increased every 3–6 doses until the SBP 
and DBP were reduced to two   standard deviations for 
their age. Dosing was either every 6 or 8 hours per day. 
The SBP was reduced 20% and the DBP 28% from 
initial parameters at doses of 0.6 ± 0.3 mg/kg/day. As 
with nicardipine, isradipine causes cerebral vasodi-
lation and must be used cautiously in children with 
intracranial pathology if at all.27,38
The most common adverse side effects reported 
with  the  use  of  CCBs  include  peripheral  edema, 
dizziness, flushing, nausea, headache, and postural 
hypotension. Other reported adverse events include 
gingival hyperplasia, chest pain, nausea and vomit-
ing, and reflex tachycardia seen with nifedipine. Side 
effects are seen more commonly as maximum dos-
ages of the drugs are reached.11,21,27
Beta-Blockers
There are limited studies evaluating BBs in children. 
Additionally, the variability of pharmacologic prop-
erties of drugs in this group and characteristics of 
each individual drug influence the selection of medi-
cation. There are few studies evaluating propranolol, Stephens et al
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a nonselective beta-blocker, as an antihypertensive in 
children. It has been used to treat hypertension for 
several years with much of the data extrapolated from 
studies in normotensive children with cardiac disease 
or portal hypertension.5 Effective dosages range from 
1 to 6 mg/kg/day. In one study of 11 children ages 
7 months to 16 years receiving 2.5 mg/kg/day, SBP 
was reduced by an average of 26 mmHg and DBP 
by an average of 20 mmHg.19,21 Atenolol, metoprolol, 
and bisoprolol are more cardioselective beta adrener-
gic antagonists. Atenolol is a β1-selective adrenergic 
antagonist that can be dosed once daily with recom-
mended doses of 1–2 mg/kg/day. It is as potent as 
propranolol when compared on a weight-by-weight 
basis and has demonstrated efficacy in adolescents.19,24 
Metoprolol succinate in an extended release prepara-
tion and was studied in two phases, a 4 week treat-
ment period and an open-label maintenance period 
for  52  weeks  in  children  ages  6–16  years  of  age. 
  Metoprolol is cardioselective but has no intrinsic sym-
pathomimetic activity. The greatest reduction in SBP 
occurred at a dose of 1 mg/kg and for DBP; reduc-
tions were greatest at 2 mg/kg compared to placebo. 
Results were seen independent of age, race, sexual 
maturity, or gender. More overweight children had a 
somewhat reduced response.39 Metoprolol reduces the 
blood pressure and heart rate response in exercise and 
reduces the sympathetic responses to mental stress 
but does not impact endurance.21 Bisoprolol fumarate 
was studied in combination with hydrochlorothiazide 
(HCT) in children ages 6–17 years of age with Stage 1 
hypertension over an eight week period. The group 
receiving the β1-cardioselective beta blocker in com-
bination with the thiazide (HCT) diuretic achieved a 
reduction in SBP of 6.8% and DBP of 8.5% but those 
that reached the target BP , 90th percentile were not 
significantly different from placebo (45% vs. 34%). 
Unfortunately there was also a significant placebo and 
dropout rate in this trial.40 Labetalol possesses addi-
tional properties besides beta blockade. Labetaolol is 
not cardioselective, has no intrinsic sympathomimetic 
properties, but has significant α-adrenergic blockage. 
The ratio of α to β blockade is estimated at seven to 
one. It has been used both orally and intravenously 
for severe hypertension.20 The α-adrenergic blockade 
counteracts the increase in systemic vascular resis-
tance caused by β2-antagonism. In a trial of 27 boys 
evaluating labetalol infusion for hypertensive crisis 
in children #24 months of age, labetalol produced a 
mean BP reduction of 20% within 8 hours.41   Similar 
results were obtained in children unable to tolerate 
oral  medications  that  were  administered  labetalol 
by infusion.19
Side  effects  attributable  to  propranolol  include 
bradycardia, hypoglycemia, anorexia, asthma exacer-
bations, night terrors, and heart block.19,21 The most 
common  side  effects  noted  in  the  metoprolol  suc-
cinate and bisoprolol trials were headache but other 
side effects reported were fatigue, upper respiratory 
tract  infection,  cough,  nasopharyngitis,  diarrhea, 
and dizziness.39,40 Labetalol can produce orthostatic 
hypotension and syncope because of reduction in the 
peripheral vascular resistance.20
Additional side effects attributable to BBs include 
fatigue, cold extremities, and sexual dysfunction.20 
Lipophilic BBs exert more central nervous system 
side effects and β1-selective blocking agents have less 
adverse effects on the lungs.24
Diuretics
There is a paucity of studies examining the use of 
diuretics for essential hypertension in children. In one 
study of 12 children ages 3–15 years involving chlo-
rthalidone, statistically significant decreases in SBP 
and  DBP  occurred.  High  dose    hydrochlorothiazide 
(50–100  mg)  compared  to  clonidine  improved  BP 
in adolescents but not to the degree of the compari-
son medication.20 Thiazide diuretics are more com-
monly used as adjunct therapy when monotherapy 
has failed to achieve the desired BP targets because of 
their synergistic effects with other antihypertensive 
medication. They particularly are recommended for 
adolescents in combination medications to improve 
adherence.5 Thiazide diuretics are ineffective when 
the GFR is ,30% from normal levels.21
Common side effects of diuretics relate to their 
effects  on  fluid  and  electrolyte  balance;  therefore 
serum  electrolytes  and  creatinine  should  be  moni-
tored. Hypokalemia, volume contraction ± hypoten-
sion,  anorexia,  nausea  and  vomiting,  pancreatitis, 
and elevated uric acid levels have been reported as 
well as ototoxicity with the use of loop diuretics.11 
Table 4 summarizes key safety information based on 
drug class. Hypertension in children and adolescents
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place in Therapy and patient 
preference
There are no adequate trials of antihypertensive med-
ications in children that compare the effectiveness of 
specific antihypertensives or classes of antihyperten-
sives on key clinical endpoints.4 Since pediatric tri-
als do demonstrate the ability of these medications 
to lower blood pressure, the choice of specific agent 
is left to the discretion of the physician who should 
take into account patient preferences as well as other 
clinical considerations. The ability of the patient to 
swallow pills, ease of dosing and risk of pregnancy 
should  be  considered.  Certain  co-morbidities  that 
favor certain classes of drugs include the use of an 
ACE or ARB in patients with diabetes and microal-
buminuria or proteinuric renal disease. Beta-blockers 
and calcium channel blockers should be considered in 
patients with migraine. In general, black children and 
adolescents do not respond as well to ACEIs at stan-
dard doses.31 Beta-blockers must be used with cau-
tion or avoided in patients with asthma and a reliable 
method of birth control must be in place for sexually 
active adolescents on ACEs or ARBs. Cough does not 
appear to limit the use of ACEs or ARBs in children 
and adolescents as it does in adults.42
In general, the child or adolescent should be started 
on  the  lowest  recommended  dose  for  the  specific 
medication and it should be titrated up, typically every 
2–4 weeks, until target BP is reached or side effects 
limit its use.4,5 After maximum doses are reached, a second 
drug can be added if the BP is still not at goal.4 The 
European guidelines recommend switching to another 
class of drugs as an alternative approach if goal BP is 
not achieved at maximum doses of a single agent.5
The Fourth Report recommends that consideration 
should be given to using a second agent with comple-
mentary  actions  to  the  first.  Examples  include ACE 
inhibitors and diuretics, or a vasodilator with a diuretic or 
beta-blocker. There is limited data and practical experi-
ence with use of fixed-dose combination medications.4 
Children and adolescents may be considered for step-
down therapy if blood pressure remains well controlled, 
especially if they achieve significant weight loss.
conclusion
Primary  hypertension  in  children  is  increasing  in 
prevalence with many cases likely going undiagnosed. 
Physicians need to screen children and adolescents 
for hypertension during routine visits and use norma-
tive percentile data for diagnosis and classification. 
Providers can consider referral for ambulatory blood 
pressure monitoring to check for possible white coat 
hypertension. Once the diagnosis is made, a clini-
cal  evaluation  must  be  performed  to  identify  the 
presence  of  co-morbidities.  Subsequent  follow-up 
blood  pressure  measurements,  therapeutic  lifestyle 
changes and pharmacologic therapies are indicated 
based on the stage of the disease. The goal of ther-
apy is to reduce blood pressure to at least ,95% in 
patients without comorbidities and ,90% in the pres-
ence of CKD, DM and target organ damage. Several 
non-pharmacologic management strategies exist for 
the treatment of primary hypertension and when they 
are not effective, pharmacologic treatment needs to be 
considered. The choice of a specific agent should take 
into account clinical considerations and patient pref-
erences. ACE inhibitors or ARBs are useful in chil-
dren, especially those with diabetes or kidney disease 
with proteinuria. Calcium channel blockers are also 
a good option in patients with diabetes or metabolic 
syndrome because they improve insulin sensitivity. 
Diuretics are also reasonable choice, although may not 
be as effective as monotherapy. Beta-blockers should 
usually be saved for second-line therapy given their 
side effect profiles, but consider them for children 
and adolescents with an additional indication such 
Table 4. Safety and monitoring of phamacologic therapy.
Ace inhibitors/ARBs
   All contraindicated in pregnancy
  Use caution in females of childbearing age
  Monitor potassium and creatinine
    Limited FDA approval to $6 years of age and to children 
with creatinine clearance $30
calcium channel blockers
  Watch for postural hypotension, flushing, and edema
Beta blockers
  May cause bradycardia-may limit dosing
  May impact athletic performance
 Avoid in insulin-dependent diabetics
    Non-cardioselective agents contraindicated in asthma 
and heart failure
Diuretics
  Monitor electrolytes upon initiation and periodically
  watch for hyperkalemia with potassium sparing diuretics
4, 11, 20, 21, 27, 42Stephens et al
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as migraines or tachycardia. In general, physicians 
should start with the lowest recommended dose and 
titrate every 2–4 weeks. If target blood pressure is not 
reached, physicians can switch to a new agent or add 
a complementary agent.
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